Overview

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Status:
Terminated

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

This trial will test the hypothesis that the combination of sirolimus, mycophenolate mofetil, and bortezomib will be effective in preventing both acute and chronic GVHD after reduced intensity allogeneic stem cell transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

PDL BioPharma, Inc.
Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Bortezomib
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus